These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34959285)

  • 21. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
    Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
    Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer.
    Wesolowski J; Tankiewicz-Kwedlo A; Pawlak D
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects of Immunotherapy for Triple-Negative Breast Cancer.
    Qiu D; Zhang G; Yan X; Xiao X; Ma X; Lin S; Wu J; Li X; Wang W; Liu J; Ma Y; Ma M
    Front Oncol; 2021; 11():797092. PubMed ID: 35111680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
    Li R; Cao L
    Front Immunol; 2023; 14():1194020. PubMed ID: 37275874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
    Yao D; Wang Y; Bian K; Zhang B; Wang D
    Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
    Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
    Front Oncol; 2021; 11():648139. PubMed ID: 34094935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
    Pawar A; Prabhu P
    Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
    Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
    Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.
    Li L; Zhang F; Liu Z; Fan Z
    Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects.
    Ahmed RF; Jameel F; Irfan M
    Crit Rev Immunol; 2019; 39(3):211-221. PubMed ID: 32421965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.
    Das K; Paul S; Ghosh A; Gupta S; Mukherjee T; Shankar P; Sharma A; Keshava S; Chauhan SC; Kashyap VK; Parashar D
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer.
    Ding YN; Ding HY; Li H; Yang R; Huang JY; Chen H; Wang LH; Wang YJ; Hu CM; An YL; Zhang ZY; Yu WP; Tang QS; Shao GL
    Acta Biomater; 2023 Sep; 167():534-550. PubMed ID: 37302734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual antibody-aided mesoporous nanoreactor for H
    Chen YT; Luo YX; Chan SH; Chiu WY; Yang HW
    J Nanobiotechnology; 2023 Oct; 21(1):385. PubMed ID: 37875918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 38. Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer.
    Fatima M; Sheikh A; Abourehab MAS; Kesharwani P
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between the Warburg effect and progression of triple-negative breast cancer.
    Liu S; Li Y; Yuan M; Song Q; Liu M
    Front Oncol; 2022; 12():1060495. PubMed ID: 36776368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
    Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
    Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.